To evaluate the contribution of the triggered immune response to the antitumor effect of reactivated p53-R279W, we injected primary W/W T-lymphoma cells into immunodeficient Rag1−/− mice, which lack functional B and T cells, followed by treatment as described earlier (Figure 4H). The gene discussed is TP53; the disease is lymphoma.